Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The company has agreement with the agency on the manufacturing, clinical and nonclinical activities required for a future marketing approval of the once-a-day pill, Xanamem.
read more
The companies have agreed to a collaboration to develop degraders to treat immune-mediated diseases.
read more
The MHRA has approved Voranigo to treat patients 12 years of age and older with grade 2 astrocytoma or oligodendroglioma.
read more
The oral drug, approved to treat primary biliary cholangitis, has been flagged by the FDA due to liver injury.
read more
Rapport has announced positive results for its phase 2a clinical trial for an oral medication treating patients with drug-resistant focal onset seizures.
read more
The oral drug aims to treat Fragile X syndrome, the most common genetic cause of autism spectrum disorder.
read more
Chinese company Hengrui has signed a $1.01 billion deal, allowing a U.S. startup to develop its oral drug to treat obstructive hypertrophic cardiomyopathy.
read more
Wayrilz is the first BTK inhibitor approved to treat the complex immune dysregulation disease.
read more
Achieve Life Sciences' oral drug, cytisinicline, supports smoking abstinence by treating nicotine dependence.
read more
The agreement will allow the two companies to collaborate on an oral small molecule program to treat inflammatory bowel disease.
read more
The study, published in the British Journal of Pharmacology, examined the therapeutic effect of forskolin on KMT2A-rearranged acute myeloid leukemia.
read more
The removal of REMS for clozapine means patients taking the antipsychotic medication no longer need to be enrolled in a restricted distribution program.
read more
The agency has begun daily publication of adverse event data from the Adverse Event Reporting System.
read more
Lilly's oral GLP-1, orforglipron, has met the primary and key secondary endpoints in a third phase 3 trial.
read more
The grant will fund a phase 2 trial for the company's orally-available, brain-penetrant lysine-gingipain inhibitor.
read more